Forecast came true

Take Profits in Sarepta Therapeutics (SRPT)
23 july

This is an update to the May 27 post: "Sarepta Due for Rebound."

Take Profits in Sarepta Therapeutics (SRPT)

Sarepta’s solid quarterly report on sales of its Exondys 51 took the market by surprise. The stock jumped to correct the undervaluation.

Insiders promptly sold shares:

Ticker

Owner

Relationship

Date

Transaction

Cost 

#Shares

Value ($)

#Shares Total

SEC Form 4

SRPT

Mahatme Sandesh

EVP, CFO & CBO

20-Jul

Option Exercise

15.38

50,000

769,107

65,359

########

SRPT

Mahatme Sandesh

EVP, CFO & CBO

21-Jul

Option Exercise

23.85

1,500

35,775

33,861

########

SRPT

Mahatme Sandesh

EVP, CFO & CBO

20-Jul

Sale

41

50,000

2,050,000

32,361

########

SRPT

Kaye Edward M. MD

Director

20-Jul

Sale

41

10,000

410,000

52,471

########

SRPT

Ruff Shamim

SVP, Regulatory Affairs & Qual

21-Jul

Option Exercise

14.12

5,888

83,133

25,450

########

SRPT

Ruff Shamim

SVP, Regulatory Affairs & Qual

20-Jul

Option Exercise

13.71

6,250

85,688

27,312

########

SRPT

Ruff Shamim

SVP, Regulatory Affairs & Qual

20-Jul

Sale

42

6,250

262,500

21,062

########

SRPT

Ruff Shamim

SVP, Regulatory Affairs & Qual

21-Jul

Sale

44

4,388

193,072

21,062

########

SRPT

Howton David T

SVP, General Counsel

21-Jul

Option Exercise

20.56

1,000

20,565

23,301

########

SRPT

Howton David T

SVP, General Counsel

20-Jul

Option Exercise

13.71

25,000

342,750

41,357

########

SRPT

Howton David T

SVP, General Counsel

20-Jul

Sale

41

25,000

1,025,000

22,301

########

Total

5,277,590

Remember, value stock members: insiders know more than the individual investor. Time to take some profits off the table. If SRPT stock dips after the U.S. government failed to repeal Obamacare, that is the time to buy the stock.

SRPT jumps from $33 to $43:

$SRPT, Sarepta Therapeutics, Inc. / H1

HZNP:

$HZNP, Horizon Pharma, Inc. / H1

Related:

  • EXAS (Exact Sciences) is a past top biotech monthly pick.
  • Acadia (ACAD) is an under-valued pick
  • Horizons (HZNP) is a value play whose stock rallied in recent days.
  • Exelixis (EXEL) is on the watch list.

* * *

Take profits in SRPT. Agree or disagree?

Sign in via StockTwits, Facebook, or Twitter to vote. “Like” this post.

Answered:
5 people

Take Profits in Sarepta Therapeutics (SRPT)

Agreed
3 people
Disagreed
2 people

Forecast came true

SRPT topped $44. Closed at $37.